Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Telix and Regeneron partner to develop radiopharmaceutical therapies for solid tumors.

flag Telix Pharmaceuticals and Regeneron Pharmaceuticals have partnered to co-develop and commercialize next-generation radiopharmaceutical therapies for solid tumors. flag The agreement includes an upfront payment of $40 million and potential milestone payments of up to $2.1 billion. flag The companies will share costs and profits equally, focusing on precision oncology and leveraging Regeneron's antibody discovery technology.

18 Articles